about
Emerging trends in the stabilization of amorphous drugs.Refining stability and dissolution rate of amorphous drug formulations.Recent advances and potential applications of modulated differential scanning calorimetry (mDSC) in drug development.Recent advances in co-amorphous drug formulations.Influence of variation in molar ratio on co-amorphous drug-amino acid systems.Preparation and recrystallization behavior of spray-dried co-amorphous naproxen-indomethacin.Multivariate Quantification of the Solid State Phase Composition of Co-Amorphous Naproxen-Indomethacin.Elucidating the Molecular Interactions Occurring during Drug Precipitation of Weak Bases from Lipid-Based Formulations: A Case Study with Cinnarizine and a Long Chain Self-Nanoemulsifying Drug Delivery System.Comparative Study of Different Methods for the Prediction of Drug-Polymer Solubility.Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures.Investigation of the Formation Process of Two Piracetam Cocrystals during Grinding.Improving co-amorphous drug formulations by the addition of the highly water soluble amino Acid, proline.The influence of pressure on the intrinsic dissolution rate of amorphous indomethacin.A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin.Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin.The significance of the amorphous potential energy landscape for dictating glassy dynamics and driving solid-state crystallisation.Melt Extrusion of High-Dose Co-Amorphous Drug-Drug Combinations : Theme: Formulation and Manufacturing of Solid Dosage Forms Guest Editors: Tony Zhou and Tonglei Li.Is there a correlation between the glass forming ability of a drug and its supersaturation propensity?Supersaturating drug delivery systems: The potential of co-amorphous drug formulations.On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.Probing Pharmaceutical Mixtures during Milling: The Potency of Low-Frequency Raman Spectroscopy in Identifying Disorder.Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.Solid state properties and drug release behavior of co-amorphous indomethacin-arginine tablets coated with Kollicoat® Protect.Floating solid cellulose nanofibre nanofoams for sustained release of the poorly soluble model drug furosemide.Characterization of Amorphous and Co-Amorphous Simvastatin Formulations Prepared by Spray Drying.Improvement of dissolution rate of indomethacin by inkjet printing.Cellulose nanofibers as excipient for the delivery of poorly soluble drugs.Quantification of microwave-induced amorphization of celecoxib in PVP tablets using transmission Raman spectroscopy.Amorphization within the tablet: Using microwave irradiation to form a glass solution in situ.Hot Melt Extrusion and Spray Drying of Co-amorphous Indomethacin-Arginine With Polymers.Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.Solid nanofoams based on cellulose nanofibers and indomethacin-the effect of processing parameters and drug content on material structure.Investigation of physical properties and stability of indomethacin-cimetidine and naproxen-cimetidine co-amorphous systems prepared by quench cooling, coprecipitation and ball milling.Influence of preparation pathway on the glass forming ability.Solid cellulose nanofiber based foams - Towards facile design of sustained drug delivery systems.Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.Application of a Salt Coformer in a Co-Amorphous Drug System Dramatically Enhances the Glass Transition Temperature: A Case Study of the Ternary System Carbamazepine, Citric Acid, and l-Arginine.Development of a screening method for co-amorphous formulations of drugs and amino acids.
P50
Q38008517-B80D1F1B-4273-4007-8FEC-01B20CEF5E01Q38206296-42090E6F-7EDF-4908-929A-F4E81ED0A13BQ38684387-0C0AE0C7-80D1-4261-82A8-4DAD2D8DB32CQ38710042-D0757870-1DA1-4592-90A2-60A2E3AAF751Q39638481-19E64318-D7CA-4368-9552-1AE98BE34755Q39808123-B2ECE1E6-A04E-48C3-958C-D0390792A760Q40375864-1BD68A40-E98C-472F-BAA1-C6D608559840Q40515570-34AB364D-50C9-4F07-B198-4AB84417695AQ40692305-C892D8E4-2127-47C2-AC6B-B319A4F44C11Q40854029-FF0F53D3-878E-4998-9AAB-D051F6087A6AQ42830904-77B5019A-F6D6-4EE4-97BA-F4A8C319BEDDQ42936240-6C70076E-D0A7-4F20-9ECB-B9D48AAB0968Q42936252-48256CB5-4808-4491-9387-44D1828FAEE7Q43753649-FE2EFF9F-F114-425C-BE9F-B64DFA021D8CQ45811011-ABBDCE5F-83DC-4105-BE6C-91F7B00827C1Q46318738-BB3305A3-3A9F-4029-969E-FCBA36E3E80EQ47183480-C1CA3606-F02A-4811-AB66-0E2B9F111AB5Q47388871-98478F9F-6C27-479F-9ED7-BF53414BF773Q47656382-0D6EF566-8FE9-4EEE-92B3-D292E4714133Q47712752-FAC5B281-1969-4F94-9598-ABBF41D11345Q47718326-4CF9B82B-13A6-4F6C-A3C2-8FCEF027E726Q47813276-B0C121A0-5621-4FDE-BCEF-020157FDC9CFQ47865775-9490F7C3-50BB-4E59-BD1F-C370F5FC96DAQ47870602-C95C23D8-2E94-4354-8C43-11EDD0382499Q48009158-D619E7F1-786A-4F09-BF44-997728E354D7Q48237580-2B885598-FF3F-466C-BAFB-01D9F458AEADQ49092618-5E318D34-7758-44DB-BAC1-98B85AA9F0E5Q49151041-49EFA777-5C9F-4EB7-995F-FB937C68C5FDQ49808563-F07520CC-8F2A-49B7-980B-B376E66C96E2Q50049189-7ED412E6-05E8-4A35-A837-A18C7883C851Q50258918-2F858195-8DBD-431B-A16A-83313229D3CDQ50277279-806DD4F3-D668-4855-9D27-63B298AD22B0Q50282539-CEDA6721-B39B-4A10-A4A5-586FD59B02B1Q50707313-317E8AAB-4DC1-4D8A-9A17-DBA4939401E1Q50756353-6EFF31C7-1B75-4B17-B8A8-F8BD12750D4BQ50875943-D71CDE68-C6EF-4DBF-B532-4083D7AE3E0CQ51100008-D130A660-F6ED-4094-A582-3E861E87897EQ51542358-0B726E2E-26F9-4152-AA00-642E2EE18AD2Q52598680-8CB8DE88-B0A9-4A90-A63B-4B60DA00BCC3Q53034696-8E5AF83C-5414-4101-8DF2-F16196144984
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Korbinian Löbmann
@ast
Korbinian Löbmann
@en
Korbinian Löbmann
@es
Korbinian Löbmann
@nl
Korbinian Löbmann
@sl
type
label
Korbinian Löbmann
@ast
Korbinian Löbmann
@en
Korbinian Löbmann
@es
Korbinian Löbmann
@nl
Korbinian Löbmann
@sl
altLabel
Loebmann K
@en
Loebmann KAM
@en
Löbmann KAM
@en
prefLabel
Korbinian Löbmann
@ast
Korbinian Löbmann
@en
Korbinian Löbmann
@es
Korbinian Löbmann
@nl
Korbinian Löbmann
@sl
P106
P1153
52364213400
P1960
jtjuLNsAAAAJ
P21
P31
P496
0000-0002-8710-6347